• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Grants Interchangeability Designation to Yuflyma, Biosimilar for Humira Across All Approved Doses

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Yuflyma gains FDA interchangeability with Humira, enhancing patient access to effective biosimilar treatments for various inflammatory conditions. Read More

The Mentorship Model: Cultivating Resilience and Leadership in Palliative Care Pharmacy

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles At the 2025 SPPCP Virtual Conference, Carolyn Hall, PharmD, BCPS, and Maria Felton Lowry, PharmD, BCPS, BCGP, presented a comprehensive and practical framework for pharmacy professionals to build effective, adaptable mentorship...

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body. Read More

Overcoming Metallo-β-Lactamases: A Review of Cefepime-Taniborbactam

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Cefepime-taniborbactam shows promise against resistant infections, but more studies are needed. Read More

T-DXd Demonstrates Safety, Efficacy After Pyrotinib Therapy Failure in Patients With HER2+ Breast Cancer

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates. Read More

Risk of Cardiovascular Event Increases With Rising Lipoprotein(a) Levels in Patients With ASCVD

by MM360 Staff | May 22, 2025 | Myeloma News

Source: Pharmacy Times articles With each increase in lipoprotein(a) level in patients with atherosclerotic cardiovascular disease (ASCVD), there was a corresponding increase in risk of experiencing an ASCVD event. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT